Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
Recruiting now
Conditions studied: Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndrome
In brief
This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are composed of DNA letters that spell out these instructions. Genomic profiling helps investigators understand why the disease develops and the instructions that led to its development. Understanding the genetic factors of the disease can also help investigator understand why the disease of some people can respond to certain therapies differently than others. The genomic profiling will be performed using bone marrow and blood samples that either have already been obtained during a previous clinical procedure or will be obtained at the time of a scheduled clinical procedure. Studying the genetic information in the cells of these samples will provide information about the origin, progression, and treatment of leukemia and myeloproliferative syndromes and myelodysplastic syndrome. Storing the bone marrow and blood samples will allow for additional research and genomic assessments to be performed in the future.
Key facts
- Study ID
- NCT04968834
- Run by
- Dana-Farber Cancer Institute
- People needed
- 300
- Starts
- 2021-06-11
- Expected to finish
- 2033-06-01
- Last updated by the study team
- 2026-07-16
Who can join
Age: any, up to 30. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age: birth to < 30 years of age
- Diagnosis:
- - Patient with acute leukemia, chronic leukemia, MDS/AML, myelodysplastic syndrome or myeloproliferative syndromes. Disease can be newly diagnosed or relapsed/refractory.
- Pathology Criteria:
- - Histologic confirmation of leukemia or myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS) at the time of diagnosis or recurrence
- Specimen Criteria:
- Sufficient sample available for genomic profiling OR bone marrow aspirate/blood draw planned for clinical care which is anticipated to allow collection of minimum specimen for testing (See Section 6.1 for description of specimen requirements)
You may not qualify if…
- Insufficient leukemia or MDS specimen available for profiling from diagnosis or recurrence (See Section 6.1); or bone marrow evaluations NOT planned for clinical care; or peripheral blast percentage <20%, or clinical blood draw not planned
Where it is running
- University of Vermont Medical Center — Burlington, Vermont, United States (enrolling)
- Maine Medical Center — Portland, Maine, United States (enrolling)
- Lifespan Cancer Institute — Providence, Rhode Island, United States (enrolling)
- Connecticut Children's Medical Center — Hartford, Connecticut, United States (enrolling)
- Dartmouth-Hitchcock — Lebanon, New Hampshire, United States (enrolling)
- Albany Medical Center — Albany, New York, United States (enrolling)
- Boston Children's Hospital — Boston, Massachusetts, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.